68 3.2.1 Caractéristiques de la population à l'initiation, p.68 ,
78 3.4.1 Caractéristiques de la population à l'arrêt, p.78 ,
88 3.5.3 Prise en charge et évolution des patients ayant présentés une toxicité grave sous anti, p.92 ,
112 4.5.3 Prise en charge et évolution des patients ayant présenté une toxicité grave sous nivolumab, p.113 ,
http://www.e-cancer.fr/Dictionnaire/I/immunotherapie, 2017. ,
Cancer immunoediting from immune surveillance to immune escape, Immunology, vol.1, issue.1, pp.1-14, 2007. ,
DOI : 10.1046/j.1440-1711.2002.01115.x
Immune-Checkpoints : les nouvelles immunothérapies anticancéreuses, Bull Cancer, vol.100, issue.6, pp.601-610, 2013. ,
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion, Science, vol.144, issue.5, pp.1565-1570, 2011. ,
DOI : 10.1016/j.cell.2011.02.013
Cancer immunoediting and ???spontaneous??? tumor regression, Pathology - Research and Practice, vol.206, issue.1, pp.1-8, 2010. ,
DOI : 10.1016/j.prp.2009.10.001
Immunité et Vaccination ? Immunologie appliquée, 2013. ,
Checkpoint immunologique comme cible thérapeutique. Oncologie, pp.354-371, 2015. ,
https://curie.fr/dossierpedagogique/immunotherapie-la-revolution-attendue-contre-le-cancer ,
Understanding Immuno-oncology ? The Interplay between the Immune System and Cancer, 2017. ,
The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. The Oncologist, pp.2-9, 2008. ,
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade, Journal of Clinical Investigation, vol.125, issue.9, pp.3377-83, 2015. ,
DOI : 10.1172/JCI80012
The blockade of immune checkpoints in cancer immunotherapy, Nature Reviews Cancer, vol.12, issue.4, 2012. ,
DOI : 10.1038/nrc3237
Immunoth??rapie dans le cancer bronchique non ?? petites cellules??: inhibition de la voie PD1/PDL1, Revue de Pneumologie Clinique, vol.71, issue.1, pp.44-56, 2015. ,
DOI : 10.1016/j.pneumo.2014.11.004
Banque de données du médicament. Monographie de l'OPDIVO®, 2017. ,
Banque de données du médicament, Monographie du KEYTRUDA®, 2017. ,
ATU http://ansm.sante.fr/Activites/Autorisations-temporaires-dutilisation-ATU/Qu-est-ce-qu-une-autorisation-temporaire-d-utilisation ,
Immune-related adverse events with immune checkpoint blockade: a comprehensive review, European Journal of Cancer, vol.54, pp.139-187, 2016. ,
DOI : 10.1016/j.ejca.2015.11.016
Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, vol.4, issue.10, pp.963-976, 2015. ,
DOI : 10.1016/j.ccell.2015.03.001
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up???, Annals of Oncology, vol.28, issue.suppl_4, pp.119-142, 2017. ,
DOI : 10.1093/annonc/mdx225
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression, JAMA Dermatology, vol.151, issue.11, pp.1206-1218, 2015. ,
DOI : 10.1001/jamadermatol.2015.1916
Inhibiteurs des points de contrôle de l'immunité : toxicités dermatologiques, digestives, rénales, cardiologiques, neurologiques et toxicités rares, La lettre du cancérologue, vol.26, pp.227-260, 2017. ,
Immunothérapie et effets indésirables endocriniens ; La lettre du cancérologue, pp.214-222, 2017. ,
Antibodymediated thyroid dysfunction during T-cell checkpoint blockade in patients with nonsmall-cell lung cancer, Ann Oncol, vol.28, issue.3, pp.583-589, 2017. ,
Toxicité pulmonaire induite par les inhibiteurs des points de contrôle de l'immunité, La lettre du cancérologue, vol.26, pp.221-226, 2017. ,
Place des anti-PD1 dans la prise en charge des m??lanomes cutan??s, Bulletin du Cancer, vol.103, issue.6, pp.4-11, 2016. ,
DOI : 10.1016/S0007-4551(16)30140-0
The Intersection of Immune-Directed and Molecularly Targeted Therapy in Advanced Melanoma: Where We Have Been, Are, and Will Be, Clinical Cancer Research, vol.19, issue.19, pp.5283-91, 2013. ,
DOI : 10.1158/1078-0432.CCR-13-2151
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032), European Journal of Cancer, vol.47, issue.10, pp.1476-83, 2011. ,
DOI : 10.1016/j.ejca.2011.04.030
Metastatic Melanoma ??? A Review of Current and Future Treatment Options, Acta Dermato Venereologica, vol.95, issue.5, pp.516-540, 2015. ,
DOI : 10.2340/00015555-2035
Banque de données du médicament. Monographie de l'INTRONA® ,
Interferon alpha for the adjuvant treatment of cutaneous melanoma, Cochrane Database of Syst Rev, vol.18, issue.6, 2013. ,
Banque de données du médicament ,
Banque de données du médicament ,
Détection des mutations de BRAF dans les tumeurs humaines : méthodes, indications et perspectives, Correspondances en Onco-Théranostic, vol.1, issue.1, 2012. ,
Banque de données du médicament ,
Banque de données du médicament, Monographie du COTELLIC® ,
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, The Lancet Oncology, vol.16, issue.4, pp.375-84, 2015. ,
DOI : 10.1016/S1470-2045(15)70076-8
Mutation, New England Journal of Medicine, vol.372, issue.4, pp.320-350, 2015. ,
DOI : 10.1056/NEJMoa1412082
URL : https://hal.archives-ouvertes.fr/hal-00872683
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial, The Lancet Oncology, vol.16, issue.8, pp.908-926, 2015. ,
DOI : 10.1016/S1470-2045(15)00083-2
Pembrolizumab versus Ipilimumab in Advanced Melanoma, New England Journal of Medicine, vol.372, issue.26, pp.2521-2553, 2015. ,
DOI : 10.1056/NEJMoa1503093
Longterm outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment, Journal of Clin Oncol, vol.35, issue.15, pp.9504-9508, 2017. ,
Cancer du poumon non à petites cellules : un guide pour les patients, 2016. ,
Epidermal growth factor receptor mutations in lung cancer, Nature Reviews Cancer, vol.64, issue.3, pp.169-81, 2007. ,
DOI : 10.1016/S1525-7304(11)70394-1
Réarrangements du gène ALK dans les cancers du poumon non à petites cellules, Correspondances en oncothéranostic, vol.1, issue.3, pp.107-110, 2012. ,
Résistance aux Inhibiteurs de Tyrosine Kinase (TKI) dans le Cancer Bronchique Non à Petites Cellules (CBNPC) Le nouveau cancérologue, pp.6-8, 2012. ,
ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer, J Clin Onco, vol.33, issue.18, pp.2004-2016 ,
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.373, issue.2, pp.123-158, 2015. ,
DOI : 10.1056/NEJMoa1504627
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial, The Lancet Oncology, vol.16, issue.3, pp.257-65, 2015. ,
DOI : 10.1016/S1470-2045(15)70054-9
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, The Lancet, vol.387, issue.10027, pp.1540-50, 2016. ,
DOI : 10.1016/S0140-6736(15)01281-7
Pembrolizumab versus Chemotherapy for PD-L1???Positive Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.375, issue.19, 2016. ,
DOI : 10.1056/NEJMoa1606774
Collection Guides Patients, 2013. ,
Traitement du carcinome r??nal m??tastatique, Progr??s en Urologie, vol.21, issue.4, pp.233-277, 2011. ,
DOI : 10.1016/j.purol.2010.11.010
Recommandations en onco-urologie 2016-2018 du CCAFU : Cancer du rein, Progr??s en Urologie, vol.27, issue.1, pp.27-52, 2016. ,
DOI : 10.1016/S1166-7087(16)30702-3
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, New England Journal of Medicine, vol.373, issue.19, pp.1803-1813, 2015. ,
DOI : 10.1056/NEJMoa1510665
Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors, World Journal of Clinical Oncology, vol.8, issue.4, pp.320-328, 2017. ,
DOI : 10.1016/j.jtho.2016.11.2228
Syndrome de Sézary, 2017. ,
Successful treatment of refractory Sezary syndrome by anti-PD-1 antibody (nivolumab), Annals of Hematology, vol.385, issue.9967, pp.687-688, 2017. ,
DOI : 10.1016/S0140-6736(14)61403-3
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study, Journal of Clinical Oncology, vol.34, issue.23, pp.34-2698, 2016. ,
DOI : 10.1200/JCO.2015.65.9789
Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial., ASCO Annual Meeting, 2017. ,
DOI : 10.1200/JCO.2017.35.18_suppl.LBA8507
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up???, Annals of Oncology, vol.27, issue.suppl_5, pp.1-27, 2016. ,
DOI : 10.1093/annonc/mdw326
Gustave Roussy à l'ASCO 2017 ? Présentation orale du Dr Caroline Robert ,
Effect of nivolumab on health-related quality of life in patients with treatment-na??ve advanced melanoma: results from the phase III CheckMate 066 study, Annals of Oncology, vol.27, issue.10, pp.1940-1946, 2016. ,
DOI : 10.1093/annonc/mdw265
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma, European Journal of Cancer, vol.67, pp.46-54, 2016. ,
DOI : 10.1016/j.ejca.2016.07.018